Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: a pilot trial. The University of Texas M.D. Anderson Cancer Center.
D000328:Adult; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation / Q000379:methods*; D002985:Clinical Protocols / Q000592:standards; D002986:Clinical Trials as Topic / Q000379:methods; D005819:Genetic Markers; D005822:Genetic Vectors; D006412:Hematopoietic Stem Cells / Q000737:chemistry / Q000473:pathology*; D006801:Humans; D007258:Informed Consent; D019868:Kanamycin Kinase; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000473:pathology*; D010770:Phosphotransferases / Q000032:analysis / Q000235:genetics; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000032:analysis / Q000235:genetics; D012190:Retroviridae; D012720:Severity of Illness Index; D014182:Transplantation, Autologous
D005819:Genetic Markers; D011994:Recombinant Proteins; D010770:Phosphotransferases; D019868:Kanamycin Kinase